ATE425987T1 - Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung - Google Patents

Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung

Info

Publication number
ATE425987T1
ATE425987T1 AT00942869T AT00942869T ATE425987T1 AT E425987 T1 ATE425987 T1 AT E425987T1 AT 00942869 T AT00942869 T AT 00942869T AT 00942869 T AT00942869 T AT 00942869T AT E425987 T1 ATE425987 T1 AT E425987T1
Authority
AT
Austria
Prior art keywords
antigen
alzheimer
disease
tau
purified
Prior art date
Application number
AT00942869T
Other languages
English (en)
Inventor
Raymond Zinkowski
Daniel Kerkman
Russel Kohnken
John Debernardis
Original Assignee
Molecular Geriatrics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Geriatrics Corp filed Critical Molecular Geriatrics Corp
Application granted granted Critical
Publication of ATE425987T1 publication Critical patent/ATE425987T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
AT00942869T 1999-06-16 2000-06-16 Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung ATE425987T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/334,582 US20020002270A1 (en) 1999-06-16 1999-06-16 Purified antigen for alzheimer's disease, and methods of obtaining and using same

Publications (1)

Publication Number Publication Date
ATE425987T1 true ATE425987T1 (de) 2009-04-15

Family

ID=23307870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942869T ATE425987T1 (de) 1999-06-16 2000-06-16 Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung

Country Status (8)

Country Link
US (4) US20020002270A1 (de)
EP (1) EP1189937B1 (de)
JP (1) JP2003503314A (de)
AT (1) ATE425987T1 (de)
AU (1) AU5743500A (de)
CA (1) CA2386393A1 (de)
DE (1) DE60041818D1 (de)
WO (1) WO2000078807A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
WO2003090599A2 (en) * 2002-04-25 2003-11-06 Brainsgate Ltd. Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
WO2004043218A2 (en) * 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
JP4628418B2 (ja) * 2004-03-08 2011-02-09 アメリカ合衆国 癌診断のための自己抗体検出
US20090299418A1 (en) * 2004-08-23 2009-12-03 Brainsgate Ltd. Concurrent bilateral spg modulation
WO2006094724A2 (en) * 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
US8021701B1 (en) * 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
EP3912643B8 (de) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunkonjugate mit einer intrazellulär spaltbaren kopplung
CA2753586A1 (en) * 2009-02-24 2010-09-02 Winton G. Gibbons Detection of complexes of tau and amyloid
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
EP3009455A1 (de) 2009-09-16 2016-04-20 Immunomedics Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
CN113671173A (zh) 2014-11-14 2021-11-19 拜尔梅里科有限公司 Ibs敏感度测试的组合物、设备以及方法
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
EP4257134A3 (de) 2015-06-25 2024-01-24 Immunomedics, Inc. Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
JP6399987B2 (ja) * 2015-09-11 2018-10-03 ヤマサ醤油株式会社 抗β２−ＧＰＩ抗体の測定法
CN105938145B (zh) * 2016-03-03 2019-03-01 浙江聚康生物工程有限公司 能与β淀粉样蛋白结合的生物大分子及其编码DNA、β淀粉样蛋白检测试剂盒及其用途
EP3497447B1 (de) 2016-07-08 2024-09-04 Biomerica, Inc. Zusammensetzungen, vorrichtungen und verfahren zum testen der depressionsempfindlichkeit
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
CN120699146A (zh) * 2025-06-11 2025-09-26 山东立菲生物产业有限公司 Aβ1-40或Aβ1-42重组抗体的制备及其在阿尔茨海默症联检试剂盒中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
FR2646425B1 (fr) * 1989-04-26 1991-08-30 Neosystem Sa Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a
US5342580A (en) 1990-04-17 1994-08-30 Alan Brenner Apparatus and method for measuring the amount of gas adsorbed on or desorbed from a solid and reactions of a gas with a solid
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
ATE398176T1 (de) * 1991-12-06 2008-07-15 Max Planck Gesellschaft Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit
CA2208329A1 (en) * 1994-12-23 1996-07-04 Albert Einstein College Of Medicine Of Yeshiva University Antigen, antibodies and diagnostic assay for alzheimer's disease
AU751784B2 (en) * 1997-08-29 2002-08-29 Innogenetics N.V. Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus

Also Published As

Publication number Publication date
US6864062B2 (en) 2005-03-08
US20050272094A1 (en) 2005-12-08
WO2000078807A1 (en) 2000-12-28
CA2386393A1 (en) 2000-12-28
EP1189937A1 (de) 2002-03-27
US20020002270A1 (en) 2002-01-03
EP1189937B1 (de) 2009-03-18
AU5743500A (en) 2001-01-09
US20080181883A1 (en) 2008-07-31
US20030113896A1 (en) 2003-06-19
DE60041818D1 (de) 2009-04-30
JP2003503314A (ja) 2003-01-28

Similar Documents

Publication Publication Date Title
ATE425987T1 (de) Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
ATE239797T1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
ATE443139T1 (de) Menschliche toll-ähliche rezeptorproteine, zugehörige reagenzien und verfahren
ATE286913T1 (de) Antikörper gegen epitope mit homologie zu auto- antigenen, verfahren zur herstellung und deren verwendungen
ATE258379T1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
ATE297465T1 (de) Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ATE145007T1 (de) Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres
EP0794195A3 (de) Antikörper BV10A4H2
DE69830315D1 (de) Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
FI960268L (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
DE69233366D1 (de) Antigene, die von Polyarthritis Rheumatoide Antikörpern erkannt werden, ihre Herstellung und ihre Anwendungen
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
DE59107756D1 (de) Monoklonale Antikörper gegen Melanom
DE69127947D1 (de) Monoklonale Antikörper gegen menschliches IgE
DE122005000034I1 (de) Verfahren zur Reinigung von waessrigen Extrakten, die allergenische Proteine enthalten, so erhalteneExtrakte und ihre Verwendung.
HUP9702359A2 (hu) Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens
DE3485054D1 (de) Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE3587681D1 (de) Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante.
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DE60236853D1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
DE69003483D1 (de) Verfahren zur Herstellung von Siliziumnitridpulver.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties